4 results about "GTPase" patented technology

Described herein, inter alia, are GTPase inhibitors and uses thereof.

Pharmaceutical compositions and therapeutic methods are provided comprising a single-domain antibody consisting of SEQ ID NO:1 and a pharmaceutically acceptable carrier. The antibody inhibits KRAS GTPase activity and inhibits phosphorylation of STAT3. In certain embodiments, inhibition of KRAS results in decreased phosphorylation of ERK1 / 2. The antibody reduces tumor cell surface PD-L1 expression and reduces VEGF production. The antibody crosses the blood-brain barrier following systemic administration and may exhibit sustained biological activity in vivo. Methods are provided for treating KRAS-mutant cancers, including pancreatic cancer and triple negative breast cancer, and for enhancing anti-tumor immunity through reduction of PD-L1 expression.

The invention belongs to the technical field of medical biology, and particularly relates to application of a detection reagent in a vascular targeted drug screening kit and a screening method. The detection reagent comprises a first detection reagent for detecting Rho GTP enzyme in experimental samples and a second detection reagent for detecting Rho kinase 2 in the experimental samples, the experimental samples comprise a first experimental sample and a second experimental sample, the first experimental sample comprises vascular endothelial cells highly expressed by Rho kinase 2, and the second experimental sample comprises vascular endothelial cells highly expressed by Rho kinase 2. The second experimental sample comprises hepatic stellate cells with high expression of Rho kinase 2; the blood vessel targeting drug is an anti-hepatic fibrosis drug taking a blood vessel as a target spot. The ROCK2 capable of targeting vascular endothelial cells and hepatic stellate cells at the same time can be effectively screened out, the anti-hepatic fibrosis medicine with the blood vessel as the target spot is further screened out, and a new thought is provided for screening of the anti-hepatic fibrosis medicine.

This invention relates to the field of electrochemical sensor sensing materials technology, and discloses a cardiovascular disease risk biomarker sensing material, its preparation method, and its application. The method includes the following steps: preparing a multi-dimensional carbon aerogel with a hierarchical porous structure; combining gold-loaded MXene with the multi-dimensional carbon aerogel to obtain a composite carbon aerogel; preparing a macromolecular electropolymerization solution containing o-phenylenediamine, labeled cMyBP-C, Rho GTPase, and calcium hydroxide; preparing a small molecule electropolymerization solution containing o-phenylenediamine, 3-NT, MDA, and Hcy; and electropolymerizing the small and macromolecular biomarkers separately using a two-step method, followed by cleaning to obtain the sensing material. This application utilizes the synergistic enhancement effect between carbon aerogel, MXene, and multi-template molecularly imprinted materials to achieve a unified high conductivity, high specific surface area, and high specificity recognition capability, enabling simultaneous, highly sensitive, and highly selective electrochemical detection of a cardiovascular disease risk biomarker spectrum composed of cMyBP-C, Rho GTPase, 3-NT, MDA, and Hcy.